Furthermore, patients of poorly differentiated BC subtypes, e.g. basal or HER2 positive BC67, 68 with higher RFX5 expression are significantly more likely to survive longer than those with lower levels of RFX5 (Fig. 3E,F). This evidence concerns the gene ERBB2 and breast cancer.